AbRegen

Therapeutic antibodies for regenerative medicine.

AbRegen uses UniSA’s patented technologies to develop first-in class antibody-based therapeutics targeting the protein Flightless-I to treat dermatological and immuno-inflammatory conditions. This approach is the only current known technology developed against the Flightless I target. Is active in multiple immuno-inflammatory conditions such as Irritable Bowel Disease and the systemic Ab treatment has a dual effect both internally (gut) and on the skin.

abregen.com.au

AbRegen